AAPL   321.77 (-1.03%)
MSFT   183.54 (-0.99%)
FB   226.99 (-1.38%)
GOOGL   1,417.59 (-1.50%)
AMZN   2,463.00 (-0.62%)
NVDA   350.60 (-0.05%)
BABA   218.39 (-0.10%)
MU   51.27 (+4.80%)
GE   7.64 (+3.80%)
TSLA   869.05 (-1.58%)
T   31.59 (+0.22%)
F   6.47 (+4.52%)
GILD   77.83 (+4.61%)
DIS   123.14 (+0.78%)
NFLX   412.86 (-2.16%)
BAC   26.57 (+2.23%)
BA   186.35 (+7.62%)
AAPL   321.77 (-1.03%)
MSFT   183.54 (-0.99%)
FB   226.99 (-1.38%)
GOOGL   1,417.59 (-1.50%)
AMZN   2,463.00 (-0.62%)
NVDA   350.60 (-0.05%)
BABA   218.39 (-0.10%)
MU   51.27 (+4.80%)
GE   7.64 (+3.80%)
TSLA   869.05 (-1.58%)
T   31.59 (+0.22%)
F   6.47 (+4.52%)
GILD   77.83 (+4.61%)
DIS   123.14 (+0.78%)
NFLX   412.86 (-2.16%)
BAC   26.57 (+2.23%)
BA   186.35 (+7.62%)
AAPL   321.77 (-1.03%)
MSFT   183.54 (-0.99%)
FB   226.99 (-1.38%)
GOOGL   1,417.59 (-1.50%)
AMZN   2,463.00 (-0.62%)
NVDA   350.60 (-0.05%)
BABA   218.39 (-0.10%)
MU   51.27 (+4.80%)
GE   7.64 (+3.80%)
TSLA   869.05 (-1.58%)
T   31.59 (+0.22%)
F   6.47 (+4.52%)
GILD   77.83 (+4.61%)
DIS   123.14 (+0.78%)
NFLX   412.86 (-2.16%)
BAC   26.57 (+2.23%)
BA   186.35 (+7.62%)
AAPL   321.77 (-1.03%)
MSFT   183.54 (-0.99%)
FB   226.99 (-1.38%)
GOOGL   1,417.59 (-1.50%)
AMZN   2,463.00 (-0.62%)
NVDA   350.60 (-0.05%)
BABA   218.39 (-0.10%)
MU   51.27 (+4.80%)
GE   7.64 (+3.80%)
TSLA   869.05 (-1.58%)
T   31.59 (+0.22%)
F   6.47 (+4.52%)
GILD   77.83 (+4.61%)
DIS   123.14 (+0.78%)
NFLX   412.86 (-2.16%)
BAC   26.57 (+2.23%)
BA   186.35 (+7.62%)
Log in

NASDAQ:MACKMerrimack Pharmaceuticals News Headlines

$3.35
-0.15 (-4.29 %)
(As of 06/4/2020 02:52 PM ET)
Add
Compare
Today's Range
$3.32
Now: $3.35
$3.50
50-Day Range
$3.33
MA: $3.56
$3.88
52-Week Range
$1.49
Now: $3.35
$7.09
Volume5,596 shs
Average Volume19,337 shs
Market Capitalization$44.82 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43

Headlines

Merrimack Pharmaceuticals (NASDAQ MACK) News Headlines

Source:
DateHeadline
Merrimack Reports First Quarter 2020 Financial ResultsMerrimack Reports First Quarter 2020 Financial Results
finance.yahoo.com - May 7 at 11:08 PM
Merrimack Pharmaceuticals: SCLC Presents A Lower Hurdle For Approval Than Initially AssumedMerrimack Pharmaceuticals: SCLC Presents A Lower Hurdle For Approval Than Initially Assumed
seekingalpha.com - April 14 at 5:51 PM
Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy UpdateMerrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update
finance.yahoo.com - April 2 at 4:41 PM
Merrimack Pharmaceuticals Inc.Merrimack Pharmaceuticals Inc.
www.barrons.com - February 24 at 12:01 AM
Merrimack Pharmaceuticals - A Better Way To Invest In BiotechnologyMerrimack Pharmaceuticals - A Better Way To Invest In Biotechnology
seekingalpha.com - February 20 at 12:55 PM
What Kind Of Share Price Volatility Should You Expect For Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)?What Kind Of Share Price Volatility Should You Expect For Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)?
finance.yahoo.com - February 7 at 2:33 PM
Hedge Funds Are Selling Merrimack Pharmaceuticals Inc (MACK)Hedge Funds Are Selling Merrimack Pharmaceuticals Inc (MACK)
finance.yahoo.com - December 22 at 11:30 PM
Merrimack Pharmaceuticals declares $0.50 dividendMerrimack Pharmaceuticals declares $0.50 dividend
seekingalpha.com - December 3 at 2:43 PM
Merrimack Pharma up 6% on $6.7M special dividendMerrimack Pharma up 6% on $6.7M special dividend
seekingalpha.com - December 3 at 2:43 PM
Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights PlanMerrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan
finance.yahoo.com - December 3 at 2:43 PM
Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special DividendMerrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend
finance.yahoo.com - December 3 at 8:49 AM
Knee Bursitis Treatment Market 2019 Research and Development- Novartis, Pfizer, Merck, Amgen, Bayer, AVEO PharmaceuticalsKnee Bursitis Treatment Market 2019 Research and Development- Novartis, Pfizer, Merck, Amgen, Bayer, AVEO Pharmaceuticals
www.marketwatch.com - November 30 at 7:49 AM
Proxy fights reach frightening level in life sciences, other industries, top attorney saysProxy fights reach 'frightening' level in life sciences, other industries, top attorney says
www.bizjournals.com - October 28 at 9:05 AM
Merrimack Pharmaceuticals Offers Significant And Uncorrelated Upside PotentialMerrimack Pharmaceuticals Offers Significant And Uncorrelated Upside Potential
seekingalpha.com - October 1 at 7:16 AM
BRIEF-JFL Capital Ends Campaign At MerrimackBRIEF-JFL Capital Ends Campaign At Merrimack
www.msn.com - September 24 at 9:20 PM
JFL Capital Ends Campaign at MerrimackJFL Capital Ends Campaign at Merrimack
finance.yahoo.com - September 24 at 9:20 PM
Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal OfficerConcert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer
www.marketwatch.com - September 23 at 3:57 PM
BRIEF-Merrimack Pharmaceuticals Says Co Enters Into Cooperation Agreement With Newtyn Management And Western StandardBRIEF-Merrimack Pharmaceuticals Says Co Enters Into Cooperation Agreement With Newtyn Management And Western Standard
www.msn.com - September 20 at 2:52 PM
Merrimack Pharmaceuticals Announces Changes to Board of DirectorsMerrimack Pharmaceuticals Announces Changes to Board of Directors
finance.yahoo.com - September 20 at 2:52 PM
Should You Buy Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) For This Reason?Should You Buy Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) For This Reason?
finance.yahoo.com - September 20 at 2:52 PM
Merrimack to pay $20M cash dividend todayMerrimack to pay $20M cash dividend today
seekingalpha.com - September 5 at 5:13 PM
Merrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special DividendMerrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special Dividend
www.nasdaq.com - September 5 at 5:13 PM
BRIEF-Merrimack - JFL Capital Management Has Launched "Unnecessary" Proxy Contest To Replace Entire Board, Effectively Seeking To Acquire CoBRIEF-Merrimack - JFL Capital Management Has Launched "Unnecessary" Proxy Contest To Replace Entire Board, Effectively Seeking To Acquire Co
www.msn.com - August 27 at 8:35 AM
Merrimack Pharmaceuticals Issues Letter to ShareholdersMerrimack Pharmaceuticals Issues Letter to Shareholders
finance.yahoo.com - August 26 at 7:44 PM
Texas investor group fighting for control of crumbling Merrimack PharmaceuticalsTexas investor group fighting for control of crumbling Merrimack Pharmaceuticals
finance.yahoo.com - August 26 at 7:44 PM
BRIEF-JFL Capital Issues Letter To Fellow Merrimack StockholdersBRIEF-JFL Capital Issues Letter To Fellow Merrimack Stockholders
www.msn.com - August 22 at 11:10 PM
JFL Capital Issues Letter to Fellow Merrimack StockholdersJFL Capital Issues Letter to Fellow Merrimack Stockholders
finance.yahoo.com - August 22 at 9:28 AM
BRIEF-Merrimack Pharmaceuticals Reschedules Annual Meeting Of ShareholdersBRIEF-Merrimack Pharmaceuticals Reschedules Annual Meeting Of Shareholders
www.msn.com - August 17 at 12:09 AM
BRIEF-Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting Of Shareholders For October 17BRIEF-Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting Of Shareholders For October 17
www.msn.com - August 17 at 12:09 AM
Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019
www.businesswire.com - August 16 at 9:46 AM
Anaplastic Astrocytoma Drug Market Scope by Trends and Opportunities to Expand Significantly by 2026Anaplastic Astrocytoma Drug Market Scope by Trends and Opportunities to Expand Significantly by 2026
www.marketwatch.com - August 12 at 11:35 PM
Merrimack Pharmaceuticals declares $1.50 dividendMerrimack Pharmaceuticals declares $1.50 dividend
seekingalpha.com - July 25 at 10:01 AM
Merrimack Declares $20 Million Special DividendMerrimack Declares $20 Million Special Dividend
finance.yahoo.com - July 25 at 10:01 AM
The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech OfferingThe Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering
www.benzinga.com - May 31 at 8:23 AM
Merrimack axes remaining staff, execs after selling assets to New York startupMerrimack axes remaining staff, execs after selling assets to New York startup
www.bizjournals.com - May 31 at 8:23 AM
Merrimack -2.6% as it decides against saleMerrimack -2.6% as it decides against sale
seekingalpha.com - May 30 at 6:42 PM
Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash DividendMerrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
finance.yahoo.com - May 30 at 6:42 PM
Merrimack Reports First Quarter 2019 Financial ResultsMerrimack Reports First Quarter 2019 Financial Results
www.prnewswire.com - May 10 at 7:59 AM
COMM 2014-UBS2 Mortgage Trust -- Moodys affirms ten classes of COMM 2014-UBS2COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2
finance.yahoo.com - May 3 at 7:14 PM
Merrimack to cut headcount after MM-310 flopMerrimack to cut headcount after MM-310 flop
seekingalpha.com - April 30 at 6:52 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACKSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
finance.yahoo.com - April 9 at 10:15 PM
Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces InvestigationMerrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
finance.yahoo.com - April 8 at 7:50 PM
Merrimack Discontinues Cancer Study Amidst LayoffsMerrimack Discontinues Cancer Study Amidst Layoffs
247wallst.com - April 5 at 7:49 PM
TrovaGene leads healthcare gainers; Merrimack Pharmaceuticals and Syros Pharmaceuticals among losersTrovaGene leads healthcare gainers; Merrimack Pharmaceuticals and Syros Pharmaceuticals among losers
seekingalpha.com - April 5 at 12:25 PM
The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather UpsetThe Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset
finance.yahoo.com - April 5 at 10:42 AM
Merrimack bails on lead candidate; shares down 9% after hoursMerrimack bails on lead candidate; shares down 9% after hours
seekingalpha.com - April 4 at 8:04 PM
Merrimack Discontinues Development of MM-310Merrimack Discontinues Development of MM-310
finance.yahoo.com - April 4 at 8:04 PM
Merrimack shelves another cancer drug, plans more layoffsMerrimack shelves another cancer drug, plans more layoffs
finance.yahoo.com - April 4 at 8:04 PM
Merrimack Pharmaceuticals, Inc. Estimate MomentumMerrimack Pharmaceuticals, Inc. Estimate Momentum
www.nasdaq.com - March 20 at 10:47 PM
Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results - PRNewswireMerrimack Reports Fourth Quarter and Full Year 2018 Financial Results - PRNewswire
www.prnewswire.com - March 7 at 8:33 AM
This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.